EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients

Deniz Türkmen iD, Jack Bowden, Jane A H Masoli, David Melzer, Luke C Pilling iD

International Journal of Molecular Sciences · 17.04.2024 · 25 (8) · 4426

DOI: 10.3390/ijms25084426 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.04.2024. Verfasst von Deniz Türkmen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology & Public Health Group, Department of Clinical & Biomedical Science, Faculty of Health & Life Sciences, University of Exeter, Exeter EX4 …. Hauptthemen laut MEDLINE: Exome Sequencing, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Liver-Specific Organic Anion Transporter 1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Ministry of National Education, Republic of Turkey, University of Exeter Medical School.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The solute carrier organic anion transporter family member 1B1 (SLCO1B1) encodes the organic anion-transporting polypeptide 1B1 (OATP1B1 protein) that transports statins to liver cells. Common genetic variants in SLCO1B1, such as *5, cause altered systemic exposure to statins and therefore affect statin outcomes, with potential pharmacogenetic applications; yet, evidence is inconclusive. We studied common and rare SLCO1B1 variants in up to 64,000 patients from UK Biobank prescribed simvastatin or atorvastatin, combining whole-exome sequencing data with up to 25-year routine clinical records. We studied 51 predicted gain/loss-of-function variants affecting OATP1B1. Both SLCO1B1*5 alone and the SLCO1B1*15 haplotype increased LDL during treatment (beta*5 = 0.08 mmol/L, p = 6 × 10−8; beta*15 = 0.03 mmol/L, p = 3 × 10−4), as did the likelihood of discontinuing statin prescriptions (hazard ratio*5 = 1.12, p = 0.04; HR*15 = 1.05, p = 0.04). SLCO1B1*15 and SLCO1B1*20 increased the risk of General Practice (GP)-diagnosed muscle symptoms (HR*15 = 1.22, p = 0.003; HR*20 = 1.25, p = 0.01). We estimated that genotype-guided prescribing could potentially prevent 18% and 10% of GP-diagnosed muscle symptoms experienced by statin patients, with *15 and *20, respectively. The remaining common variants were not individually significant. Rare variants in SLCO1B1 increased LDL in statin users by up to 1.05 mmol/L, but replication is needed. We conclude that genotype-guided treatment could reduce GP-diagnosed muscle symptoms in statin patients; incorporating further SLCO1B1 variants into clinical prediction scores could improve LDL control and decrease adverse events, including discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Exome SequencingHydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1AgedFemaleHumansMaleMiddle AgedAtorvastatinPolymorphism, Single NucleotideSimvastatinTreatment OutcomeUK BiobankUnited Kingdom

Stichwörter der Autor:innen

SLCO1B1cholesterolclinical responseepidemiologyexome sequencing variantspharmacogenomicsstatin

Substanzen

AtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1SimvastatinSLCO1B1 protein, human

Autor:innen und Institutionen

  • Epidemiology & Public Health Group, Department of Clinical & Biomedical Science, Faculty of Health & Life Sciences, University of Exeter, Exeter EX4 4QD, UK.
  • Exeter Diabetes Group (ExCEED), Department of Clinical & Biomedical Science, Faculty of Health & Life Sciences, University of Exeter, Exeter EX4 4QD, UK.
  • Department of Genetics, Novo Nordisk Research Centre Oxford, Innovation Building, Old Road Campus, Oxford OX3 7BN, UK.
  • Department of Healthcare for Older People, Royal Devon University Healthcare NHS Foundation Trust, Exeter EX2 5DW, UK.

ORCID-Profile: Deniz Türkmen, Luke C Pilling

Förderung

  • Medical Research Council
  • Ministry of National Education, Republic of Turkey
  • University of Exeter Medical School

Zitieren

APA

Türkmen, D., Bowden, J., Masoli, J. A. H., Melzer, D., & Pilling, L. C. (2024). SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients. International Journal of Molecular Sciences, 25(8), 4426. https://doi.org/10.3390/ijms25084426

Vancouver

Türkmen D, Bowden J, Masoli JAH, Melzer D, Pilling LC. SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients. International Journal of Molecular Sciences. 2024;25(8):4426. doi:10.3390/ijms25084426

BibTeX
@article{Trkmen2024,
  author = {Türkmen, Deniz and Bowden, Jack and Masoli, Jane A H and Melzer, David and Pilling, Luke C},
  title = {SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {8},
  pages = {4426},
  doi = {10.3390/ijms25084426}
}
Kostenlos starten →